Latest stories on NRSN
NRSN Downgraded by HC Wainwright & Co. -- Rating Changed to Neutral
GuruFocus34 · bearishanalyst
NeuroSense downgraded at H.C. Wainwright on extended PrimeC timelines
The Fly34 · bearishanalyst
NeuroSense downgraded to Neutral from Buy at H.C. Wainwright
The Fly34 · bearishanalyst
NeuroSense Adds NfL Data to PrimeC Canadian ALS Submission
TipRanks58 · neutralproduct/pr
NeuroSense Therapeutics (NRSN) Delays Health Canada Submission to Incorporate New ALS Treatment Data
GuruFocus42 · neutralgeneral
NeuroSense adds new data to its Canadian submission of ALS candidate
The Fly58 · neutralproduct/pr
NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data
StockTitan58 · neutralproduct/pr
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
PR Newswire58 · neutralproduct/pr
NeuroSense Therapeutics Moves to Early PrimeC Commercialization in U.S.
TipRanks63 · neutralproduct/pr
NeuroSense Files U.S. Patent to Extend PrimeC into Traumatic Brain Injury
TipRanks58 · neutralproduct/pr
NeuroSense Files U.S. Patent Application for Traumatic Brain Injury
StockTitan56 · neutralproduct/pr
NRSN sets Nov. 10 Nasdaq hearing as PrimeC milestones line up into Q1 2027
October 14, 2026
MarketChameleon58 · neutralgeneral
NeuroSense (NRSN) sets a Nov. 10 Nasdaq hearing while targeting a December 2026 PrimeC filing in Canada
October 13, 2026
MarketChameleon54 · neutralgeneral
NeuroSense secures Nasdaq hearing date as PrimeC approaches milestones
The Fly58 · neutralgeneral
NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones
PR Newswire58 · neutralgeneral
NeuroSense downgraded to Neutral from Buy at Roth Capital
The Fly34 · bearishanalyst
NeuroSense Provides Update on Nasdaq Listing Compliance
StockTitan53 · neutralgeneral
NeuroSense Provides Update on Nasdaq Listing Compliance
PR Newswire53 · neutralgeneral
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
PR Newswire55 · neutralgeneral
NeuroSense target adjusted to $52 from $8 at H.C. Wainwright
The Fly34 · bearishanalyst
NeuroSense Therapeutics GAAP EPS of -$2.10 beats by $1.83
Seeking Alpha56 · neutralearnings
NeuroSense Provides Business Update and Progress for the First Half of 2026
PR Newswire55 · neutralgeneral
NeuroSense Provides Business Update and Progress for the First Half of 2026
StockTitan55 · neutralgeneral
Neurosense Therapeutics Ltd trading halted, news pending
The Fly48 · neutralgeneral
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire56 · neutralgeneral